Boston Scientific Corporation BSX
- Market cap
- $64.7B
- P/E
- 17.7×
Follow BSX
Boston Scientific Corporation (BSX) P/B ratio
As of 25 September 2026, Boston Scientific Corporation (BSX) trades at a P/B ratio of 2.6×. Over the past ten years it has ranged from 2.5× (June 2026) to 7.1× (February 2025); the current reading is higher than 1% of that period. That is in line with the Medical Devices industry median of 2.5× and in line with the Healthcare sector median of 2.5×.
P/B ratio, daily
Annual
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 5.8× | (3.44%) |
| FY2024 | 6.0× | 38.81% |
| FY2023 | 4.3× | 14.90% |
| FY2022 | 3.7× | 3.04% |
| FY2021 | 3.6× | 9.38% |
| FY2020 | 3.3× | (26.72%) |
| FY2019 | 4.5× | (18.94%) |
| FY2018 | 5.6× | 13.22% |
| FY2017 | 4.9× | 11.98% |
| FY2016 | 4.4× | 12.74% |
Quarterly
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 2.5× | (30.16%) |
| Mar 2026 | 3.6× | (38.12%) |
| Dec 2025 | 5.8× | (5.77%) |
| Sep 2025 | 6.1× | (12.76%) |
| 42 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| PHG Koninklijke Philips N.V. compare | 1.8× |
| MDT Medtronic PLC compare | 2.2× |
| BSX Boston Scientific Corporation | 2.6× |
| GEHC GE HealthCare Technologies Inc. compare | 2.7× |
| STE STERIS plc compare | 2.8× |
| ABT Abbott Laboratories compare | 3.4× |
| SYK Stryker Corporation compare | 4.4× |
| EW Edwards Lifesciences Corporation compare | 4.6× |
| DXCM DexCom, Inc. compare | 12.6× |
| Medical Devices industry median | 2.5× |
| Healthcare sector median | 2.5× |
| Market median | 1.8× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on BSX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement